Comparative Pharmacology
Head-to-head clinical analysis: FLUOROMETHOLONE versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOROMETHOLONE versus TRIESENCE.
FLUOROMETHOLONE vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce phospholipase A2 inhibitory proteins, thereby reducing prostaglandin and leukotriene synthesis. Exhibits anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
1-2 drops of 0.1% suspension in conjunctival sac 2-4 times daily; severe cases: every 4 hours initially, then taper. Ointment: 0.5 inch ribbon 1-3 times daily.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Clinical Note
moderateFluorometholone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Gatifloxacin."
Clinical Note
moderateFluorometholone + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Rosoxacin."
Clinical Note
moderateFluorometholone + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: 1.3–2.2 hours; However, the pharmacodynamic half-life (duration of adrenal suppression) is longer (~24–36 hours) due to receptor-mediated effects.
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Renal (primarily as metabolites): ~70%; Fecal: ~20%; Unchanged in urine: <5%
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category A/B
Category C
Corticosteroid
Corticosteroid
Fluorometholone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluorometholone is combined with Trovafloxacin."